Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ta/T1 Clear all
Not yet recruiting Phase 1 Interventional

A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

NCT07725796
View directory record Official record
Conditions
Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
UGN-501
Biological
Lead sponsor
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 7:02 PM EDT
Active, not recruiting Phase 3 Interventional

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773
View directory record Official record
Conditions
Bladder Carcinoma in Situ (CIS)
Interventions
ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Drug
Lead sponsor
Fidia Farmaceutici s.p.a.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
6
States / cities
Gilbert, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 3, 2026, 7:02 PM EDT
Recruiting No phase listed Observational

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

NCT07763197
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 3, 2026, 7:02 PM EDT
Recruiting Phase 2 Interventional

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

NCT07322263
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions
Intravesical Gemcitabine and Docetaxel
Drug
Lead sponsor
Michael A. O'Donnell
Other
Eligibility
18 Years to 99 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 3, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Results available

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

NCT03258593
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Durvalumab, Vicineum, Acetaminophen, Antihistamine, Bladder Biopsy, TURBT, Cystoscopy, Urine cytology, Electrocardiogram, CT, MRI
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 7:02 PM EDT
Completed Phase 2 Interventional

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
La Jolla, California • Orange, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 3, 2026, 7:02 PM EDT
Recruiting Phase 2 Interventional

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

NCT03945162
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Interventions
Ruvidar® (TLD-1433) bladder infusion and PDT
Combination Product
Lead sponsor
Theralase® Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 3, 2026, 7:02 PM EDT
Not listed Phase 3 Interventional

Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

NCT00003725
View directory record Official record
Conditions
Bladder Cancer
Interventions
valrubicin, conventional surgery
Drug · Procedure
Lead sponsor
Anthra Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 3, 2026, 7:02 PM EDT
Terminated No phase listed Observational

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

NCT06026332
View directory record Official record
Conditions
Bladder Cancer
Interventions
ADSTILADRIN
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
31
States / cities
Gilbert, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 3, 2026, 7:02 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT04452591
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
45
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 7:02 PM EDT
Withdrawn Phase 1 Interventional

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

NCT04109092
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
E7766
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 3, 2026, 7:02 PM EDT
Withdrawn Phase 1 Interventional

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

NCT03552796
View directory record Official record
Conditions
Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I
Interventions
Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein
Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 3, 2026, 7:02 PM EDT
Withdrawn Phase 4 Interventional

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

NCT06390111
View directory record Official record
Conditions
Bladder Cancer, Ta/T1, CIS
Interventions
nadofaragene firadenovec
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Little Rock, Arkansas • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 3, 2026, 7:02 PM EDT